Apply for this study

Treating Restless Leg Syndrome in Women with ALD - Part 1

Study in progress
Recruitment in progress
In Phase 1 of this research study, we want to learn more about how common restless legs syndrome (RLS) is in women with X-linked adrenoleukodystrophy (ALD). You may be eligible to take part in Phase 1 of the study if you have been diagnosed with ALD and are a female age 18 years and older. We anticipate that 50 people at Massachusetts General Hospital (MGH) and 50 people at the University Medical Center (UMC) of Amsterdam will participate in Phase 1 of the study. Participation in Phase 1 may include the following visits:
ALD Eligibility Remote Pre-Screening Visit (V1): This visit will be conducted over the phone with a study coordinator. It will consist of a review of medical and demographic history to determine if you are eligible to participate in the study.
RLS Diagnostic Remote Visit (V2): Eligible patients will be interviewed by both an expert in ALD (Dr. Florian Eichler) and an expert in RLS (Dr. John Winkelman) to determine if you have any symptoms of RLS. This visit will also involve completion of a series of questionnaires including the following: The 12-Item Multiple Sclerosis Walking Scale (MSWS-12), Spasticity Screening Tool, The Generalized Anxiety Disorder Assessment (GAD-7), The Patient Health Questionnaire (PHQ-9), and The 36-Item Short Form Survey (SF-36).
RLS Severity Remote Visit (V3): Patients who meet the diagnostic criteria for RLS will undergo an additional telephone interview with Dr. Eichler or Dr. Winkelman to determine the severity of RLS symptoms.
Study duration:
23 mois
Start of the study:
March 2023
End of recruitment:
January 2025
End of the study:
January 2025
  • Authorized in United States of America, Netherlands
  • Recruitment of patients ongoing in United States of America, Netherlands
Inclusion criteria
  • Age : greater than or equal to 18 years
  • Sex : female
  • To have one of the following pathologies : X-linked Adrenoleukodystrophy / ALD (ABCD1), Adrenomyeloneuropathy / AMN
  • Subject : patient
I satisfy to all the inclusion criteria
Study location
  • MGH, Boston, United States of America
  • Amsterdam UMC, Amsterdam, Netherlands
I choose my site